Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Warner-Lambert found guilty of promoting neurontin off label.

Larkin M.

Lancet Neurol. 2004 Jul;3(7):387. No abstract available.

PMID:
15228033
2.

Drug maker to pay $430 million in fines, civil damages.

[No authors listed]

FDA Consum. 2004 Jul-Aug;38(4):36-7.

3.

Doctor sues company over unethical marketing.

Charatan F.

BMJ. 2002 May 25;324(7348):1234. No abstract available.

4.

Pfizer pleads guilty, but drug sales continue to soar.

Lenzer J.

BMJ. 2004 May 22;328(7450):1217. No abstract available.

5.

The truth is out there.

[No authors listed]

Lancet Neurol. 2003 May;2(5):261. No abstract available.

PMID:
12849163
6.

Doctor explains why he blew the whistle.

Petersen M.

N Y Times Web. 2003 Mar 12:C1, C2. No abstract available.

PMID:
12812161
7.

Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: avoiding a pyrrhic victory.

Blackwell AE, Beck JM; Dechert, L.L.P, Philadelphia, USA.

Food Drug Law J. 2003;58(3):439-62. No abstract available.

PMID:
14626985
8.

Court papers suggest scale of drug's use: lawsuit says doctors were paid endorsers.

Petersen M.

N Y Times Web. 2003 May 30:C1, C2. No abstract available.

PMID:
12812176
9.

The future of off-label marketing regulations in the post-Sorrell era.

Iraggi J.

Seton Hall Law Rev. 2013;43(3):1137-63. No abstract available.

PMID:
23802338
10.

Gabapentin (Neurontin) for chronic pain.

[No authors listed]

Med Lett Drugs Ther. 2004 Apr 12;46(1180):29-31. No abstract available.

PMID:
15079144
11.

FDA approved new drug bulletin. Gabapentin (neurontin).

[No authors listed]

RN. 1994 Jul;57(7):39-40. No abstract available.

PMID:
8047795
12.

Neurontin: expanding the clinical experience. Proceedings of a symposium. Cannes, France, June 5, 1998.

[No authors listed]

Epilepsia. 1999;40 Suppl 6:S1-74. No abstract available.

13.

Parke-Davis whistle-blower speaks at last.

Larkin M.

Lancet Neurol. 2003 May;2(5):264. No abstract available.

PMID:
12849165
14.

False Claims Act prosecution did not deter off-label drug use in the case of neurontin.

Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J.

Health Aff (Millwood). 2011 Dec;30(12):2318-27. doi: 10.1377/hlthaff.2011.0370.

15.

Confounding factors in off-label drug use.

Greenberg PE, Pike C, Sisitsky T.

Health Aff (Millwood). 2012 Feb;31(2):460; author reply 460. doi: 10.1377/hlthaff.2011.1394. No abstract available.

16.

Gabapentin. CI 945, GOE 3450, Neurontin.

[No authors listed]

Drugs R D. 1999 Dec;2(6):385-9. No abstract available.

PMID:
10763447
17.

Use of drugs for off-label indications: living in the same world.

Barbuto JP.

J Manag Care Pharm. 2003 Nov-Dec;9(6):570-1. No abstract available.

18.

Gabapentin (NEURONTIN)--a novel anticonvulsant.

Murdoch LA.

Axone. 1994 Dec;16(2):56.

PMID:
7727298
19.

Management of restless legs syndrome with gabapentin (Neurontin)

Mellick GA, Mellick LB.

Sleep. 1996 Apr;19(3):224-6. No abstract available.

PMID:
8723380
20.

Gabapentin--a new antiepileptic drug.

[No authors listed]

Drug Ther Bull. 1994 Apr 21;32(4):29-30.

PMID:
7635023

Supplemental Content

Support Center